Prophylactic TCRαβ+/CD19+- Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Blood C cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This protocol tests the safety and determines the maximum tolerated or administered dose of αβT/B dep-DLI after allo-SCT in high-risk hematologic malignancies. The study uses a dose-escalation design with monitoring for dose-limiting toxicities through day 28 after infusion, followed by an expansion cohort at the identified dose. Primary goals are safety and determination of MTD/MAD; secondary goals include feasibility, additional safety parameters, and preliminary efficacy. All participants are followed for 2 years post-infusion. The intervention consists of allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with high-risk myeloid or lymphoid malignancies determined to be eligible to undergo allo-SCT including but not limited to the conditions listed below. These criteria apply at the disease diagnosis or any time prior to the cyto-reductive therapy given before the planned conditioning:

  * Refractory acute myelogenous (AML) or lymphoid leukemia (ALL)
  * Relapsed AML or ALL
  * AML in European LeukemiaNet (ELN) high risk per cytogenetic and mutation
  * Any patients with minimal residual disease (MRD+) disease by flow cytometry or with active disease (not in complete remission (CR)) prior to allo-SCT
  * Myelodysplastic syndromes (MDS) with 5% or more blasts at initial diagnosis, or anytime during their treatment prior to allo-SCT.
  * Myelodysplastic syndrome (MDS) high risk or very high risk per Revised International Prognostic Scoring System (IPSS-R) or Molecular International Prognostic Scoring System (IPSS-M)
  * Chronic myelogenous leukemia (CML) in chronic phase failed 3 or more treatments, in accelerated or blast phase
  * High risk primary myelofibrosis (PMF) per Dynamic International Prognostic Scoring System (DIPSS)-plus or Mutation-enhanced International Prognostic Scoring System for Transplant-age Patients (MIPSS70+)
  * PMF in accelerated or blast phase
  * Recurrent or refractory malignant lymphoma or Hodgkin's disease with less than a partial response at transplant
  * High risk chronic lymphocytic leukemia defined as no response or stable disease to the most recent treatment regimen
  * Other high risk hematologic malignancies for which allo-SCT is deemed clinically necessary per PI and based on institutional standards
* The donor for the allo-SCT must be:

  * Related AND
  * Matched OR mismatched OR haploidentical at HLA-A, -B, -C, and -DRB1 by molecular methods
* ECOG performance score of 0-2
* Ability to understand and willingness to sign written informed consent document
* Willing to comply with all study procedures and be available for the duration of the study
* Individuals in sexual relationships that could result in pregnancy or impregnation of their partner must use an acceptable method of contraception§ from enrollment until 4 weeks after completing study treatment.

Exclusion Criteria:

• Poor organ function as follows (According to the pre-transplant workups results):

* Creatinine ≥ 2.0 mg/dL
* SGOT and SGPT ≥ 5 x ULN. Liver biopsy per clinician discretion.
* Bilirubin ≥ 3 x ULN (unless Gilbert's syndrome)
* DLCO \< 50% corrected for hemoglobin
* Left ventricular ejection fraction or shortening fraction \< 40%

NOTE: Exceptions to the above organ function exclusion criteria are allowable only with assent of the PI since the risks and benefits must be addressed for patients with potentially incurable hematologic malignancies. Such exceptions will be clearly documented in the subject's research record and will not be considered a deviation.

* Patients with uncontrolled intercurrent illness
* Patients with psychiatric illness/social situations that would limit compliance with study requirements

Where it's running

• UW Carbone Cancer Center
  Madison, Wisconsin, United States Recruiting

Study contacts

• Principal investigator: Hongtao Liu, MD, PhD — UW Carbone Cancer Center
• Study coordinator: Cancer Connect
• Email: clinicaltrials@cancer.wisc.edu
• Phone: 800-622-8922

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tempus Open Link registry for cancer patients using Olivia platform

  This registry tests whether Olivia can securely enroll cancer patients and combine their health data from EHRs and patient-reported outcomes to build a large, de-identified dataset.

  Recruiting Tempus AI · Chicago, Illinois · NCT07756034

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• Leflunomide to prevent CMV reactivation after haploidentical stem cell transplant

  This study tests whether leflunomide can prevent CMV reactivation in adults undergoing haploidentical hematopoietic stem cell transplantation.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 2 other locations · NCT07709013

• MK-1045-006: testing a new treatment for B-cell cancers like CLL and SLL

  This trial will test MK-1045 in people with relapsed or treatment‑refractory CLL/SLL to see if it’s safe and how well it works.

  Recruiting at 8 sites Phase 2 Merck Sharp & Dohme LLC · Medellín, Antioquia and 7 other locations · NCT07709000

• Predicting bleeding risk in patients with severe thrombocytopenia using a viscoelastic and clinical score

  We test a new score that combines viscoelastic test results with clinical data to see if we can predict bleeding risk in adults with malignant hematologic disorders and very low platelets.

  Recruiting Centre Hospitalier Annecy Genevois · Épagny, Auvergne-Rhône-Alpes · NCT07653672

• Ruxolitinib to prevent graft-versus-host disease after allogeneic stem cell transplant

  This trial will test whether adding ruxolitinib to standard drugs better prevents chronic graft-versus-host disease in adults receiving an allogeneic stem cell transplant for blood cancers.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07359859

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.